Healthcare / Medical DevicesNasdaqCM
$0.11
+0.02 (+15.96%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $1.6M · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$141257
P/E
N/A
•EV/EBITDA
6.8x
↓ROE
-5.8%
↓Gross Margin
23.8%
↓Debt/Equity
0.35
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-20.6%
FCF CAGR
—
FCF margin
49.9%
FCF / Net income
-4.58x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $9.8M · net income $-1.1M · FCF $4.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $9.8M | $9.8M | $11.5M | $13.6M | $19.7M |
| Net Income | $-1.1M | $-1.1M | $-3.5M | $112030.00 | $865210.00 |
| EBITDA | $344657.00 | $344657.00 | $-1.7M | $2.1M | $4.7M |
| EPS | — | — | -2700.00 | 77.26 | 558.20 |
| Gross Margin | 23.8% | 23.8% | 24.9% | 30.5% | 22.4% |
| Operating Margin | -9.1% | -9.1% | -32.1% | 3.6% | 9.3% |
| Net Margin | -10.9% | -10.9% | -30.4% | 0.8% | 4.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.35 | 0.35 | 1.02 | 0.92 | 0.63 |
| Current Ratio | 1.71 | 1.71 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $4.9M | $4.9M | $-11.5M | $1.6M | $-4.3M |
| Returns | |||||
| ROE | -5.8% | -5.8% | -26.5% | 1.1% | 8.7% |
| Valuation | |||||
| EV/EBITDA | 6.76 | 6.76 | — | — | — |
| P/B | 0.00 | 0.00 | 4.62 | — | — |
| Growth & Yield | |||||
| Revenue Growth | -14.4% | -14.4% | -15.2% | -31.2% | — |
| EPS Growth | — | — | -3594.6% | -86.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-100.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-2700.00 → n/d
Residual
-100.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.